ReviewJACC. Basic to translational science2025
What Is Cardiometabolic HFpEF and How Can We Study it Preclinically?
Review in JACC. Basic to translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07336316 (Multimodal Cardiovascular Magnetic Resonance Imaging for Cardiometabolic Pre-HF and HFpEF), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multimodal Cardiovascular Magnetic Resonance Imaging for Cardiometabolic Pre-HF and HFpEF: Integrated Phenotyping, Precision Diagnosis, and Risk Stratification
Who cites it
6 citing papers in PubMed.
- Integrating untargeted metabolomics and machine learning to reveal an aberration of sphingolipid metabolism in cardiometabolic HFpEF.Diabetology & metabolic syndrome · 2026Article
- Cardiometabolic Heart Failure with Preserved Ejection Fraction (HFpEF): Epidemiology, Mechanisms, and the Role of Lifestyle Modification.Journal of cardiovascular development and disease · 2026Review
- Purine Metabolism Alterations in Patients with Chronic Heart Failure: A Cross-Sectional Study of Associations with Iron Status, Oxidative Stress, and Anemia.Metabolites · 2026Article
- What Exactly Is Cardiometabolic HFpEF: A Phenotype or an Endotype?Circulation. Heart failure · 2026Article
- Cardiac and renal sympathetic nerve activation in early-stage HFpEF: insights fromThe international journal of cardiovascular imaging · 2026Article
- Gut Microbiota and Short-Chain Fatty Acids in Cardiometabolic HFpEF: Mechanistic Pathways and Nutritional Therapeutic Perspectives.Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cardiometabolic heart failure with preserved ejection fraction (HFpEF) has emerged as a distinct and dominant endotype of HFpEF. Driven by prevalent comorbidities, its incidence and prevalence are projected to continue to rise amid the current global pandemic of obesity and metabolic disease. Recognizing the characteristic clinical and molecular features of cardiometabolic HFpEF is paramount for developing an efficacious therapeutic arsenal and improving clinical outcomes, challenges in which success to date has been modest. Studying relevant and clinically informative animal models of cardiometabolic HFpEF can afford valuable insights into the molecular underpinnings of this syndrome, allowing the possibility of novel advances with clinical relevance. Here, we outline the clinical and molecular features that define cardiometabolic HFpEF as a distinct endotype. We also discuss the bona fide animal models of cardiometabolic HFpEF currently available, as well as methods for developing new models.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.